KPI is a clinical-stage biopharma company focused on the development of new medicines that have the potential to transform the standard of care and save or improve patients’ lives. Our pipeline includes TriRima, a reversible inhibitor of monoamine oxidase-A (RIMA) for the treatment of depression, and KP544, a novel mechanism for the treatment of neurodegenerative disorders such as Alzheimer's Disease and prevention of neuropathy caused by chemotherapeutic agents.